Trametinib dimethyl sulfoxide. MAP kinase kinase 1 and 2 (MEK 1/2) inhibitor oncolytic

Dysregulation of the Ras/Raf/MEK/ERK signaling pathway (also known as the mitogen-activated protein [MAP] kinase pathway) has been implicated in many types of cancer, including melanoma, pancreas, colon and lung cancer, and this pathway has become an attractive target for therapeutic development. There has been some success in targeting Raf, but previously developed MEK inhibitors have yielded limited clinical benefit. This review focuses on the preclinical and clinical development of trametinib dimethyl sulfoxide (GSK-1120212B), a selective MEK 1/2 inhibitor.